Termine

Termine
  • Posttransplantatives Lymphom
  • Termine
  • Studiengruppen-Veranstaltungen

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients